Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis
NCT05844449Phase 3Enrolling by invitation
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of vanzacaftor, tezacaftor, deutivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Aug 2023; status: enrolling by invitation.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05844449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844449.